R8005
RPMI-1640 培养基
Hybri-Max™, Modified, with L-glutamine, 4500 mg/L glucose and 15mM HEPES, without sodium bicarbonate, powder, suitable for hybridoma
别名:
RPMI 1640培养基
登录 查看组织和合同定价。
选择尺寸
变更视图
关于此项目
Quality Level
form
powder
technique(s)
cell culture | hybridoma: suitable
impurities
endotoxin
components
phenol red: 0.0053 g/L
L-glutamine: 0.3 g/L
HEPES: 3.5745 g/L
NaHCO3: no
glucose: 4.5 g/L (Dextro)
shipped in
ambient
storage temp.
2-8°C
General description
RPMI-1640培养基是在1966年由Moore及其同事在Roswell Park Memorial Institute开发的。该培养基通过对McCoy的5A培养基进行改良配制而成，用于在悬浮培养中支持淋巴母细胞生长，但后来经证还可支持各种不同贴壁依赖性细胞。RPMI 1640最初配合血清补充剂使用，但经证在无血清的情况下也能支持多种细胞系。它还广泛应用于杂交细胞融合方案和生长。该培养基适用于人正常白细胞和肿瘤白细胞=培养。
Preparation Note
按照每升培养基16.4克粉末配制。
补充2.0 g/L碳酸氢钠。
Legal Information
Hybri-Max is a trademark of Sigma-Aldrich Co. LLC
Still not finding the right product?
Explore all of our products under RPMI-1640 培养基
存储类别
11 - Combustible Solids
wgk
WGK 2
flash_point_f
Not applicable
flash_point_c
Not applicable
实验方案
粉末培养基及盐混合物极具吸湿性，应注意防潮。
Powdered media and salt mixtures are extremely hygroscopic and should be protected from atmospheric moisture.
相关内容
Instructions
Sven D Willger et al.
PLoS pathogens, 4(11), e1000200-e1000200 (2008-11-08)
At the site of microbial infections, the significant influx of immune effector cells and the necrosis of tissue by the invading pathogen generate hypoxic microenvironments in which both the pathogen and host cells must survive. Currently, whether hypoxia adaptation is
Michael D Lewis et al.
The American journal of tropical medicine and hygiene, 81(6), 1041-1049 (2009-12-10)
Trypanosoma cruzi, the agent of Chagas disease, can be subdivided into six discrete typing units (DTUs), TcI, TcIIa, TcIIb, TcIIc, TcIId or TcIIe, each having distinct epidemiologically important features. Dozens of genetic markers are available to determine the DTU to
Ryoichi Arita et al.
Diabetes, 58(1), 215-226 (2008-10-09)
Leukocyte adhesion in retinal microvasuculature substantially contributes to diabetic retinopathy. Involvement of the Rho/Rho kinase (ROCK) pathway in diabetic microvasculopathy and therapeutic potential of fasudil, a selective ROCK inhibitor, are investigated. Localization of RhoA/ROCK and Rho activity were examined in
全球贸易项目编号
| 货号 | GTIN |
|---|---|
| R8005-10X1L | 04061836807405 |
| R8005-10L | 04061836807399 |